Study finds durable responses to immunotherapy in rare angiosarcomas
In a small study of 16 patients with the rare cancer angiosarcoma, tumors in four patients partially or completely responded to treatment with a combination of the immunotherapy drugs ipilimumab and nivolumab.
Linear Mode
